Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,297 across all filing types
Latest filing 2024-08-22 Interim / Quarterly Rep…
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is an official announcement of interim financial results for the first half of 2024 for Bavarian Nordic A/S. It contains detailed financial tables, including income statements, balance sheets, and cash flow statements, as well as management commentary on business performance and future guidance. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-08-22 English
Bavarian Nordic Announces First Half 2024 Results
Report Publication Announcement Classification · 95% confidence The document is an announcement titled 'Bavarian Nordic Announces First Half 2024 Results'. It provides a summary of financial highlights, business progress, and guidance. Crucially, the document concludes with an 'Attachment' section that explicitly links to the full 'Interim Report H1 2024'. Following the 'Menu vs Meal' rule, this document serves as the announcement of the report rather than the full report itself, making it a Report Publication Announcement (RPA). H1 2024
2024-08-22 Danish
Earnings Release 2024
Earnings Release Classification · 99% confidence The document is a short announcement (4310 characters) titled "Company Announcement" detailing a new contract award for vaccine supply and confirming updated financial guidance for the year. It is not a full annual report (10-K), an interim report (IR), or a detailed management discussion (MDA). It is a specific, material update regarding business operations and financial outlook, often released outside of scheduled quarterly filings. Since it announces key financial results (revenue/EBITDA guidance confirmation) but is not the full earnings release (ER) which typically contains detailed period financials, it most closely aligns with an Earnings Release (ER) or a general Regulatory Filing (RNS). Given that it explicitly confirms and updates the full-year revenue and EBITDA guidance based on new contract wins, it functions as an Earnings Release (ER) announcing the key financial outcome, even if it's not the comprehensive quarterly report. However, because it is a specific, non-standard announcement about a contract and guidance update, and not the formal quarterly results document itself, the most appropriate classification is the general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses this format for guidance updates. Given the strong focus on confirming the upper end of the revenue guidance, ER is a strong candidate, but RNS is safer for non-standard announcements. Since it contains material financial guidance updates, I will lean towards ER, as it serves the function of an early earnings announcement/update. FY 2024
2024-08-21 English
Regulatory Filings 2024
Regulatory Filings Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a new contract for vaccines, confirming that this order was expected and has led to the confirmation of updated financial guidance for the year (revenue and EBITDA). This type of announcement, which provides key operational updates and immediately revises financial outlooks, strongly aligns with an Earnings Release (ER) or a general regulatory announcement. Since it is a specific, material update that impacts financial expectations, it is classified as an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), or a mere announcement of a report (RPA). The document length (4113 chars) is substantial enough to contain key results/updates, making ER more appropriate than RNS/RPA.
2024-08-21 Danish
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
Regulatory Filings Classification · 95% confidence The document is a company announcement from Bavarian Nordic regarding a new contract for vaccine delivery. While it contains financial guidance updates, it is structured as a standard corporate press release/regulatory announcement (Selskabsmeddelelse nr. 24 / 2024). It does not fit the criteria for a full quarterly or annual report, nor is it a standalone earnings release (ER) as it focuses on a specific contract win. Given the nature of the announcement and the presence of a 'Vedhæftet fil' (Attached file) link, it functions as a regulatory filing/announcement. Since it does not fit into more specific categories like M&A or Share Issues, 'RNS' (Regulatory Filings) is the most appropriate classification.
2024-08-21 Danish
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
Regulatory Filings Classification · 95% confidence The document is a press release from Bavarian Nordic announcing a new vaccine supply contract and updating their financial guidance for 2024. While it contains financial figures, it is an announcement of a contract win and a guidance update rather than a formal quarterly or annual report. It does not fit the criteria for a full report (10-K or IR) and is not a mere publication announcement (RPA) because it contains substantive business news and updated financial guidance. It is best classified as a general regulatory filing (RNS) as it serves as a company announcement regarding business operations and financial outlook.
2024-08-21 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.